Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$5.5 million.

  • Cytek Biosciences' Net Income towards Common Stockholders fell 68214.67% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.8 million, marking a year-over-year decrease of 2619.35%. This contributed to the annual value of -$6.0 million for FY2024, which is 5044.45% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Net Income towards Common Stockholders is -$5.5 million, which was down 68214.67% from -$5.6 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Net Income towards Common Stockholders peaked at $9.6 million during Q4 2024, and registered a low of -$11.4 million during Q1 2025.
  • Over the past 5 years, Cytek Biosciences' median Net Income towards Common Stockholders value was -$2.0 million (recorded in 2022), while the average stood at -$2.2 million.
  • The largest annual percentage gain for Cytek Biosciences' Net Income towards Common Stockholders in the last 5 years was 38150.29% (2022), contrasted with its biggest fall of 208137.25% (2022).
  • Cytek Biosciences' Net Income towards Common Stockholders (Quarter) stood at $346000.0 in 2021, then skyrocketed by 919.94% to $3.5 million in 2022, then surged by 55.94% to $5.5 million in 2023, then surged by 75.23% to $9.6 million in 2024, then tumbled by 156.81% to -$5.5 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$5.5 million for Q3 2025, versus -$5.6 million for Q2 2025 and -$11.4 million for Q1 2025.